Dengue illness index-A tool to characterize the subjective dengue illness experience
JournalPLoS neglected tropical diseases
MetadataShow full item record
AbstractDengue virus infections are a major cause of febrile illness that significantly affects individual and societal productivity and drives up health care costs principally in the developing world. Two dengue vaccine candidates are in advanced clinical efficacy trials in Latin America and Asia, and another has been licensed in more than fifteen countries but its uptake has been limited. Despite these advances, standardized metrics for comparability of protective efficacy between dengue vaccines remain poorly defined. The Dengue Illness Index (DII) is a tool that we developed thru refinement of previous similar iterations in an attempt to improve and standardize the measurement of vaccine and drug efficacy in reducing moderate dengue illness. The tool is designed to capture an individual's overall disease experience based on how the totality of their symptoms impacts their general wellness and daily functionality. We applied the DII to a diary card, the Dengue Illness Card (DIC), which was examined and further developed by a working group. The card was then refined with feedback garnered from a Delphi methodology-based query that addressed the adequacy and applicability of the tool in clinical dengue research. There was overall agreement that the tool would generate useful data and provide an alternative perspective to the assessment of drug or vaccine candidates, which in the case of vaccines, are assessed by their reduction in any virologically confirmed dengue of any severity with a focus on the more severe. The DIC needs to be evaluated in the field in the context of vaccine or drug trials, prospective cohort studies, or during experimental human infection studies. Here, we present the final DIC resulting from the Delphi process and offer its further development or use to the dengue research community.
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85054466182&origin=inward; http://hdl.handle.net/10713/9857
- Development of standard clinical endpoints for use in dengue interventional trials.
- Authors: Tomashek KM, Wills B, See Lum LC, Thomas L, Durbin A, Leo YS, de Bosch N, Rojas E, Hendrickx K, Erpicum M, Agulto L, Jaenisch T, Tissera H, Suntarattiwong P, Collers BA, Wallace D, Schmidt AC, Precioso A, Narvaez F, Thomas SJ, Edelman R, Siqueira JB, Cassetti MC, Dempsey W, Gubler DJ
- Issue date: 2018 Oct
- Clinical evaluation of dengue and identification of risk factors for severe disease: protocol for a multicentre study in 8 countries.
- Authors: Jaenisch T, Tam DT, Kieu NT, Van Ngoc T, Nam NT, Van Kinh N, Yacoub S, Chanpheaktra N, Kumar V, See LL, Sathar J, Sandoval EP, Alfaro GM, Laksono IS, Mahendradhata Y, Sarker M, Ahmed F, Caprara A, Benevides BS, Marques ET, Magalhaes T, Brasil P, Netto M, Tami A, Bethencourt SE, Guzman M, Simmons C, Quyen NT, Merson L, Dung NT, Beck D, Wirths M, Wolbers M, Lam PK, Rosenberger K, Wills B
- Issue date: 2016 Mar 11
- Efficacy of a tetravalent dengue vaccine in children in Latin America.
- Authors: Villar L, Dayan GH, Arredondo-García JL, Rivera DM, Cunha R, Deseda C, Reynales H, Costa MS, Morales-Ramírez JO, Carrasquilla G, Rey LC, Dietze R, Luz K, Rivas E, Miranda Montoya MC, Cortés Supelano M, Zambrano B, Langevin E, Boaz M, Tornieporth N, Saville M, Noriega F, CYD15 Study Group
- Issue date: 2015 Jan 8
- Symptomatic Dengue in Children in 10 Asian and Latin American Countries.
- Authors: L'Azou M, Moureau A, Sarti E, Nealon J, Zambrano B, Wartel TA, Villar L, Capeding MR, Ochiai RL, CYD14 Primary Study Group, CYD15 Primary Study Group
- Issue date: 2016 Mar 24
- [Dengue fever: from disease to vaccination].
- Authors: Teyssou R
- Issue date: 2009 Aug